Search
Mesoridazine
go.drugbank.com/drugs/DB00933ApprovedWithdrawnA phenothiazine antipsychotic with effects similar to chlorpromazine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesFelbamate
go.drugbank.com/drugs/DB00949ApprovedIt has a weak inhibitory effect on GABA receptor binding sites.
Categories: NMDA Receptor Antagonists, Cytochrome P-450 SubstratesIsoniazid
go.drugbank.com/drugs/DB00951ApprovedInvestigationalAntibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsNorgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigationalNorgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with eth...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigationalPindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythm...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsZaleplon
go.drugbank.com/drugs/DB00962ApprovedIllicitZaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLetrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affe...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCinacalcet
go.drugbank.com/drugs/DB01012ApprovedInvestigationalCinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMethoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnAn inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTopotecan
go.drugbank.com/drugs/DB01030ApprovedInvestigationalAn antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors